目的 分析醫(yī)改新政策下遼寧省腫瘤醫(yī)院新型抗腫瘤藥物的使用情況,為規(guī)范其管理及合理應(yīng)用提供參考。方法 運(yùn)用藥物經(jīng)濟(jì)學(xué)的金額分析法和用藥頻度(DDDs)分析法對(duì)2018-2021年遼寧省腫瘤醫(yī)院新型抗腫瘤藥物的使用數(shù)據(jù)進(jìn)行統(tǒng)計(jì)分析。結(jié)果 醫(yī)改新政策下,新型抗腫瘤藥物品種逐年增加,2019年銷(xiāo)售金額和構(gòu)成比激增,之后呈平穩(wěn)趨勢(shì)。大多數(shù)藥物DDDs逐年上升,限定日費(fèi)用(DDC)下降的藥物近50%,兩者前10位排序均變化不大,藥品銷(xiāo)售金額排序(B)/DDDs排序(A)大于0.90的藥物比例基本恒定(70%~80%)。結(jié)論 醫(yī)院新型抗腫瘤藥的使用基本合理。伴隨醫(yī)改新政策的實(shí)施,新型抗腫瘤藥物品種增多、價(jià)格降低,患者受益的同時(shí)也應(yīng)對(duì)其使用加強(qiáng)監(jiān)管。

Objective To investigate the application of novel antineoplastic drugs in Liaoning Cancer Hospital and Institute under the new policy of medical reform, and provide references for standardizing the management and rational application.Methods The data of novel antineoplastic drugs in Liaoning Cancer Hospital and Institute from 2018 to 2021 were calculated and analyzed by using defined daily cost (DDC) analysis of pharmacoeconomics and defined daily dose system (DDDs) analysis.Results Under new medical reform policies, the variety of novel antineoplastic drugs increased year by year. Consumption sum and constituent ratio increased sharply in 2019, and then the trend was stable. The DDDs of most drugs increased year by year. DDC of nearly half of the drugs decreased, while there was little change in the top 10 ranking of DDDs and DDC. The proportion of drugs with ratio of sequence of consumption sum (B)/sequence of DDDs (A) greater than 0.90 was basically constant, accounting for 70% — 80%.Conclusion The utilization of novel antineoplastic drugs in our hospital is basically reasonable. With the implementation of new medical reform policies, the variety of novel antineoplastic drugs has increased and the price has decreased, which is benefit for patients. But the supervision of the usage still need to be strengthened.

R979.1